Helios receives innovation award

Helios receives innovation award

Helios CORP hits a home run and a triple at the recent, national, IFT conference and convention that was held June 12-14. Helios Corp received, on behalf of their distribution partner, Summit Resource Group, the top Innovation & Technology Award at the recent National IFT Conference and Convention.


Helios CORP hits a home run and a triple at the recent, national, IFT conference and convention that was held June 12-14.

Helios Corp received, on behalf of their distribution partner, Summit Resource Group, the top "Innovation & Technology Award" at the recent National IFT Conference and Convention. The award was based on the translation of their novel calcium ingredient, NC-518, lending science from the Nutra category into the Functional Foods category. They were able to show applications for NC-518 into the beverage and dairy categories. The idea was that the end use manufacturer's might utilize the USA based, NC-518 Phase I and Phase II human clinical studies which showed increases in bone density, and apply the results to their label claims such as "improves bone health".

The second acknowledgement at the IFT was towards Helios CORP's work with KGK Synergize on the ingredient called Diabetinol. Again, the distribution partner, Summit Resource Group was chosen to be part of IFT's science tour, or the elite Trends & Solutions tour, due to their work in the weight loss/ diabetes category with Diabetinol. Show participants were provide with summary information concerning the USA based Phase I and Phase II human clinical studies that accompanied the all natural, citrus based Diabetinol.

Helios CORP's president, Michael Jeffers, was interviewed on the show floor, and this interview was inserted into "You Tube.com" by the IFT management team. His comment summarized that Diabetinol was proven in both human clinical studies to improve the glucose/ insulin profile when the body intakes carbohydrates/ sugar and in turn requires an insulin response to manage this surge. In the USA based Phase II clinical the active participants were able to meet their ADA levels and meet AACE guidelines when taking Diabetinol.

Helios CORP continues to translate cultural remedies into commercial applications for the benefit of end users in the Nutritional and Functional Foods categories while providing these end use partners with the clinical science to support their label claims. The regulatory landscape is such that science based companies like Helios CORP can provide extensive benefits to companies via. their USA based human clinical work, re: www.HeliosCorp.net.

About Helios: Helios Corp. is a privately owned and global company that develops new, nutritional ideas, science, and cultural remedies that can be translated into commercial applications for the benefit of nutra and food manufacturers and consumers. Helios branded ingredients come with Phase I and USA based Phase II human clinical studies. Claims and representations are based on the information, data, clinical studies and remedies as provided by our science and manufacturing partners.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish